Metastatic Colorectal Cancer

Oncology·MeSH: Colorectal Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

129 drugs in development·33 companies·40 clinical trials

Drug Pipeline by Phase

Phase 3(30)
DrugCompany
amivantamabGH Research PLC (GHRS)
amivantamabGH Research PLC (GHRS)
amivantamabGH Research PLC (GHRS)
amivantamab ivGH Research PLC (GHRS)
AvelumabIGM Biosciences, Inc. (IGMS)
Biweekly FOLFIRIIGM Biosciences, Inc. (IGMS)
CetuximabBRISTOL MYERS SQUIBB CO (BMY)
CMAB009IGM Biosciences, Inc. (IGMS)
DrugSummit Therapeutics Inc. (SMMT)
FOLFIRIAmneal Pharmaceuticals, Inc. (AMRX)
FOLFIRI ProtocolIGM Biosciences, Inc. (IGMS)
folfiri regimenAMGEN INC (AMGN)
FOLFIRI+cetuximabIGM Biosciences, Inc. (IGMS)
FOLFOXIGM Biosciences, Inc. (IGMS)
FOLFOXAmneal Pharmaceuticals, Inc. (AMRX)
FOLFOX-4IGM Biosciences, Inc. (IGMS)
FOLFOX-7IGM Biosciences, Inc. (IGMS)
FOLFOX+QL1706+CetuximabKYNTRA BIO INC. (KYNB)
Fruquintinib Combined With ChemotherapyIGM Biosciences, Inc. (IGMS)
leucovorinGH Research PLC (GHRS)
LeucovorinBRISTOL MYERS SQUIBB CO (BMY)
mFOLFOXIRIIGM Biosciences, Inc. (IGMS)
nis793Novartis AG (NVS)
PanitumumabIGM Biosciences, Inc. (IGMS)
regorafenibIGM Biosciences, Inc. (IGMS)
SintilimabIGM Biosciences, Inc. (IGMS)
Standard ChemotherapyBioNTech SE (BNTX)
Standard systemic therapyIGM Biosciences, Inc. (IGMS)
TiragolumabIGM Biosciences, Inc. (IGMS)
Young TILFilana Therapeutics Inc. (FLNA)
Phase 2(48)
DrugCompany
350 mg leronlimabCytoDyn Inc. (CYDY)
700 mg leronlimabCytoDyn Inc. (CYDY)
AB680Arcus Biosciences, Inc. (RCUS)
AldesleukinFilana Therapeutics Inc. (FLNA)
Biweekly FOLFIRIMerus N.V. (MRUS)
Biweekly FOLFIRIREGENXBIO Inc. (RGNX)
Biweekly FOLFIRIKYNTRA BIO INC. (KYNB)
Biweekly Modified FOLFOX6REGENXBIO Inc. (RGNX)
Biweekly Modified FOLFOX6KYNTRA BIO INC. (KYNB)
Biweekly Modified FOLFOX6IGM Biosciences, Inc. (IGMS)
CAPOXMerus N.V. (MRUS)
cetuximabPFIZER INC (PFE)
CTX-009Compass Therapeutics, Inc. (CMPX)
Elraglusib Oral TabletACTUATE THERAPEUTICS, INC. (ACTU)
EmavusertibADMA BIOLOGICS, INC. (ADMA)
FloxuridineBridgeBio Oncology Therapeutics, Inc. (BBOT)
folfiriCardiff Oncology, Inc. (CRDF)
folfiriASTRAZENECA PLC (AZN)
folfiriONCOLYTICS BIOTECH INC (ONCY)
folfiriNovartis AG (NVS)
FOLFIRI regimenREGENXBIO Inc. (RGNX)
folfoxCardiff Oncology, Inc. (CRDF)
FOLFOXENANTA PHARMACEUTICALS INC (ENTA)
FOLFOX regimenIGM Biosciences, Inc. (IGMS)
Fosifloxuridine NafalbenamideIGM Biosciences, Inc. (IGMS)
HydroxychloroquineIGM Biosciences, Inc. (IGMS)
InavolisibIGM Biosciences, Inc. (IGMS)
LeucovorinAbbVie Inc. (ABBV)
m-FOLFOX-6 regimenArcus Biosciences, Inc. (RCUS)
mFOLFOXIRIREGENXBIO Inc. (RGNX)
mFOLFOXIRIKYNTRA BIO INC. (KYNB)
mFOLFOXIRIMerus N.V. (MRUS)
modified folfox6Novartis AG (NVS)
navicixizumabOncoMed Pharmaceuticals Inc (OMED)
OmpenaclidCrinetics Pharmaceuticals, Inc. (CRNX)
OmpenaclidENANTA PHARMACEUTICALS INC (ENTA)
OmpenaclidMerus N.V. (MRUS)
OmpenaclidREGENXBIO Inc. (RGNX)
onvansertibCardiff Oncology, Inc. (CRDF)
OnvansertibIGM Biosciences, Inc. (IGMS)
Onvansertib (Onv)Cardiff Oncology, Inc. (CRDF)
panitumumabAbbVie Inc. (ABBV)
PDS01ADCBridgeBio Oncology Therapeutics, Inc. (BBOT)
PDS01ADCIGM Biosciences, Inc. (IGMS)
pelareorepONCOLYTICS BIOTECH INC (ONCY)
tislelizumabNovartis AG (NVS)
Vincristine Sulfate LiposomeENANTA PHARMACEUTICALS INC (ENTA)
ZN-c3Zentalis Pharmaceuticals, Inc. (ZNTL)
Phase 1(28)
DrugCompany
AdagrasibIGM Biosciences, Inc. (IGMS)
BET Bromodomain Inhibitor ZEN-3694Amneal Pharmaceuticals, Inc. (AMRX)
BNT314BioNTech SE (BNTX)
CetuximabZentalis Pharmaceuticals, Inc. (ZNTL)
DivarasibIGM Biosciences, Inc. (IGMS)
EmavusertibENANTA PHARMACEUTICALS INC (ENTA)
EmavusertibMerus N.V. (MRUS)
EmavusertibBridgeBio Oncology Therapeutics, Inc. (BBOT)
EncorafenibZentalis Pharmaceuticals, Inc. (ZNTL)
EncorafenibENANTA PHARMACEUTICALS INC (ENTA)
FOLFIRIBridgeBio Oncology Therapeutics, Inc. (BBOT)
FOLFIRIREGENXBIO Inc. (RGNX)
FOLFIRIENANTA PHARMACEUTICALS INC (ENTA)
FOLFOXREGENXBIO Inc. (RGNX)
FOLFOXBridgeBio Oncology Therapeutics, Inc. (BBOT)
JNJ-89402638BridgeBio Oncology Therapeutics, Inc. (BBOT)
JNJ-89402638REGENXBIO Inc. (RGNX)
JNJ-89402638Merus N.V. (MRUS)
JNJ-89402638ENANTA PHARMACEUTICALS INC (ENTA)
JNJ-89402638IGM Biosciences, Inc. (IGMS)
Leucovorin CalciumADMA BIOLOGICS, INC. (ADMA)
Leucovorin CalciumCURIS INC (CRIS)
LPM6690176IGM Biosciences, Inc. (IGMS)
me-344Lite Strategy, Inc. (LITS)
panitumumabAMGEN INC (AMGN)
PumitamigMerus N.V. (MRUS)
RP3Replimune Group, Inc. (REPL)
SY-5609IGM Biosciences, Inc. (IGMS)
Phase 1/Phase 2(1)
DrugCompany
RegorafenibArcus Biosciences, Inc. (RCUS)

Compare drugs

alymsys vs Cyramzaalymsys vs krazatialymsys vs vykoura

Frequently asked questions

How many drugs are in development for Metastatic Colorectal Cancer?

BioSniper tracks 129 drugs in development for Metastatic Colorectal Cancer across 33 companies.

How many clinical trials target Metastatic Colorectal Cancer?

There are 40 clinical trials targeting Metastatic Colorectal Cancer tracked by BioSniper.

What is the prevalence of Metastatic Colorectal Cancer?

The estimated prevalence of Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.

Deep-dive into Metastatic Colorectal Cancer

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis